Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells

Qiaohong Nong, Shaokang Yu, Hui Hu, and Xue Hu

Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China

Correspondence should be addressed to Qiaohong Nong; 13510331825@139.com

Received 15 October 2021; Revised 3 November 2021; Accepted 7 November 2021; Published 27 November 2021

Academic Editor: Osamah Ibrahim Khalaf

Copyright © 2021 Qiaohong Nong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. In order to investigate the effect of lncRNA FOXD2-AS1 on breast cancer cells proliferation, migration, and drug resistance as well as its molecular mechanism.

Methods. Real-time PCR was used to detect the expression of breast cancer tissues and cells from patients admitted to our hospital and the expression of lncRNA FOXD2-AS1 in MCF-7/ADR in adriamycin- (ADR-) resistant breast cancer cells. After interfering with or overexpressing lncRNA FOXD2-AS1 in MCF-7/ADR cells, cell proliferation, apoptosis, invasion, and migration were detected using CCK-8, flow cytometry, Transwell assay, and scratch test, respectively. The protein levels of PI3K, p-PI3K, AKT, and p-AKT in the PI3K/AKT signaling pathway were detected by Western blot. Results. lncRNA FOXD2-AS1 was upregulated in breast cancer tissues and cells and increased cell drug resistance to ADR. Downregulation of lncRNA FOXD2-AS1 inhibited invasion and migration of MCF-7/ADR cells, promoted apoptosis, increased chemosensitivity of MCF-7/ADR cells, and inhibited the activity of PI3K/AKT signaling pathway in MCF-7/ADR cells. Conclusions. lncRNA FOXD2-AS1 can promote the proliferation, invasion, migration, and drug resistance of breast cancer cells, inhibit apoptosis, and accelerate the development of breast cancer by positively regulating the PI3K/AKT signaling pathway.

1. Introduction

Cancer is one of the leading causes of death worldwide [1]. Breast cancer is one of the most common cancer diseases in women and the second most fatal cancer worldwide, with a gradually increasing mortality rate in China [2]. So far, significant progress has been made in surgical treatment, chemotherapy, targeted drugs, and other treatments. Due to the lack of early effective biomarkers, patients are primarily diagnosed in the late stage of the disease, resulting in a poor prognosis. Therefore, there is a need to find effective biomarkers to diagnose early breast cancer and improve patient survival effectively.

Studies have shown that patients receiving long-term chemotherapy often develop chemoresistance [3]. For example, adriamycin (ADR) is an effective chemotherapeutic drug commonly used for breast cancer treatment. Still, its drug has become a significant clinical problem and a fundamental reason for treatment failure [4]. However, the mechanism of drug resistance and treatment is still completely unclear. Tumorigenesis is characterized by uncontrolled cell proliferation with a high rate of metastasis [5, 6]. Therefore, determining the mechanism of abnormal regulation of proliferation and metastasis of drug-resistant cells is the key to urgent identification.

Long noncoding RNAs (lncRNAs) are noncoding RNAs that are greater than 200 nucleotides in length. A variety of lncRNAs to date have been found to be closely related to the development and metastasis of breast cancer [7, 8]. It has been shown that the expression level of lncRNA HOTAIR in breast cancer tissues is significantly higher than that in paracancerous tissues, and it can promote the metastasis of breast cancer cells [9]. lncRNA MALAT1 has also been demonstrated to be highly expressed in breast cancer cells and is closely related to the development and metastasis of tumors [10]. It has also been reported that lncRNA DILA1 can promote the drug resistance of breast cancer cells to tamoxifen by stabilizing
the CyclinD1 protein [11]. Chen et al. [12] found that overexpression of lncRNA GAS5 significantly increased the sensitivity of breast cancer cells to ADR. Zhang et al. [13] demonstrated that lncRNA XIST promotes chemotherapy resistance to ADR in breast cancer cells by upregulating ANLN through sponge miR-200c-3p. These studies suggest that lncRNAs are involved in breast cancer development and drug resistance. It has been shown that lncRNA FOXD2-AS1 is a newly discovered lncRNA involved in developing a variety of tumors, which was first reported in hepatocellular carcinoma studies [14]. Subsequently, several studies have found that the expression level of lncRNA FOXD2-AS1 is upregulated in ovarian, gastric, and bladder cancer and is closely related to the proliferation, migration, invasion, and tumor prognosis of tumor cells, which can be used as a potential target for cancer treatment and prognosis [15–17]. In addition, lncRNA FOXD2-AS1 is also involved in tumor drug resistance. lncRNA FOXD2-AS1 regulates cisplatin resistance in non-small-cell lung cancer through the miR-185-5p-SIX1 axis [18]. Silencing of lncRNA FOXD2-AS1 inhibits proliferation and drug resistance of temozolomide-resistant glioma cells via the miRNA-98-5p/CPEB4 axis [19]. It has also been stated that lncRNA FOXD2-AS1 can regulate breast cancer malignancy and tumorigenesis by regulating the miR-150-5p/PFN2 axis [20]. Therefore, we speculate that lncRNA FOXD2-AS1 may play a role in drug resistance in breast cancer cells. However, related studies have not been reported. In this study, MCF-7/ADR, an adriamycin-resistant breast cancer cell, was used as the study target. The expression of lncRNA FOXD2-AS1 in MCF-7 and MCF-7/ADR cells was first determined. Meanwhile, the expression of lncRNA FOXD2-AS1 in MCF-7/ADR cells was intervened to further explore its role in ADR resistance in breast cancer cells. This study may provide some reference for future clinical prevention of drug resistance in breast cancer.

2. Materials and Methods

2.1. Tissue Specimens. A total of 60 cases of tumor tissue and 60 cases of adjacent normal tissue were collected from patients with breast cancer admitted to our hospital from May 2020 to March 2021. Samples were immediately frozen in liquid nitrogen and kept at -80°C. All diagnosis was confirmed by the Department of Pathology of all tissue samples, and all patients have not received chemotherapy or radiation therapy. All patients have signed the informed consent form, and the Peking University of Shenzhen Hospital committee has approved this study (2020-023).

2.2. Cell Culture. Human normal breast cells (MCF-10A), human breast cancer cells (MCF-7), and adriamycin-resistant breast cancer cells (MCF-7/ADR) were purchased from Shanghai Cell Research Institute, China. MCF-10A cells were cultured in DMEM/F-12 medium (Gibco, USA), and MCF-7 cells were cultured in 1640 medium (Gibco, USA), both containing 10% fetal bovine serum (FBS; Gibco, USA) and 1% penicillin-streptomycin; MCF-7/ADR cells were cultured in 1640 medium supplementary with 20% FBS and 1% penicillin-streptomycin. Incubation was done in an incubator containing 5% CO2 and 95% humidity at 37°C.

2.3. Cell Transfection. MCF-7/ADR cells were cultured to logarithmic growth period, digested and passaged, diluted to 2 × 106 cells/mL, and seeded in 6-well plates. Transfection was performed when cells were cultured to a confluence of 50% to 600%. lncRNA FOXD2-AS1 overexpression vector (FOXD2-AS1) and unloaded vector, lncRNA FOXD2-AS1 siRNA fragment (si-lncRNA FOXD2-AS1), and control siRNA NC (siNC) were transfected into cells according to the instructions of Lipo2000 transfection kit (Thermo Fisher Scientific, USA). FOXD2-AS1 overexpression vector and unloaded vector, FOXD2-AS1 siRNA fragment, and control siRNA NC were designed and synthesized by Guangzhou Ruibo Biotechnology Co., Ltd. (China).

2.4. qRT-PCR. Cells were collected, and total cellular RNA was extracted with Total RNA extraction kit (Takala, Japan) and stored at −80°C. RNA was then reverse transcribed into cDNA using a reverse transcription-PCR kit (Takala, Japan). After the concentration and purity of the synthesized cDNA were detected, an appropriate amount of cDNA was taken for reaction according to the instructions of real-time PCR reagents (Takala, Japan). The reaction program was as follows: 95°C for 1 min; 95°C for 40 s, 58°C for 40 s, and 72°C for 45 s, for 35 cycles; and 72°C for 10 min. Data analysis was performed with the 2^ΔΔCt method. The primer sequences used are shown in Table 1.

2.5. CCK-8. Cells after drug treatment or transfection were seeded in 96-well plates at 5000 cells per well. After 24 h of culturing, 10 μL of CCK-8 solution and 90 μL of complete fresh medium were added to each well. The 96-well plate was placed in the incubator for another 2 h, and the absorbance value at the wavelength of 450 nm was detected with a microplate reader.

2.6. Apoptosis. Annexin V-allophycocyanin (APC) apoptosis detection kit (BD Pharmingen, San Jose, USA) was used to detect apoptosis in transfected MCF-7/ADR cells. The cells were washed twice with precooled PBS buffer with a 1 × Binding Buffer used to prepare a 1 × 106 cells/mL suspension. 100 μL of cells was added to the flow tube with an appropriate amount of Annexin V and nucleic acid dye, gently mixed well, and placed in a dark place at room temperature for 15 minutes. Cells were washed once using 1 × Binding Buffer, and the supernatant was removed. 100 μL of 1 × Binding Buffer was used to dissolve 0.5 μg of SAv-FITC reagent before adding to the flow tube and gently mix well. 5 μL of PI was added and left at room temperature in the dark for 15 min. 400 μL of 1 × Binding Buffer was added to each assay tube, and the results were measured by a FACScan flow cell flow system (Becton Dickinson, San Diego, CA, USA) within 1 h.

2.7. Transwell Assay. Matrigel was removed from -20°C and put at 4°C overnight to become liquid and diluted at 1:6 in
Table 1: qRT-PCR primer sequence.

| Gene name | Primer sequence |
|-----------|----------------|
| IncRNA FOXD2-AS1 | F: 5'-TGGACCTAGCTGAGCTCCA-3'  
R: 5'-AGTGAAGGGATGCACACCTG-3'  
F: 5'-GGAGATGGCAGCTCCTC-3' |
| GAPDH | R: 5'-TCAGTGGTGAGCTGCC-3' |

- serum-free medium at 4°C. 100 μL of Matrigel was added to the center of the upper chamber of the Transwell and placed at 37°C for 3-5 h until solid state. 100 μL of transfected cells was added to the upper chamber, and 500 μL containing complete medium was added to the lower layer for culture. After 24 hours of culture, they were fixed with 4% paraformaldehyde, stained with crystal violet solution, observed under a microscope, and photographed for statistical analysis.

2.8. Scratch Test. A ruler and a permanent marker were used to evenly draw a horizontal line at an interval of 0.5-1 cm on the bottom surface of the 6-hole plate. At least 5 lines were to pass through each hole. Transfected MCF-7/ADR cells were added to the upper chamber, and 500 μL containing complete medium was added to the lower layer for culture. After 24 hours of culture, they were fixed with 4% paraformaldehyde, stained with crystal violet solution, observed under a microscope, and photographed for statistical analysis.

2.9. Western Blot. The cells in each group were lysed with RIPA lystate for 20 min, and the cells were disrupted by sonication in an ice bath to collect proteins and detect protein concentrations. After performing SDS-PAGE to separate proteins, they were transferred on to PVDF membranes. After blocking for 1 h at room temperature, the membranes were incubated with primary antibodies P38K, p-P38K, AKT, and p-AKT (all purchased from CST, USA) overnight at 4°C. The membrane was washed twice, then added with diluted enzyme-labeled secondary antibody, incubated at room temperature for 1 h, and developed using an exposure meter. β-Actin was used as an internal reference to analyze protein levels.

2.10. Statistical Analysis. The experimental data were statistically analyzed using SPSS 21.0 software. The results were expressed as the mean ± standard deviation (SD). Comparisons between two groups were performed using Student’s t-test, and comparisons of multiple groups were performed using one-way analysis of variance. P < 0.05 was recorded as statistically significant.

3. Results

3.1. IncRNA FOXD2-AS1 Is Highly Expressed in Breast Cancer and Enhanced Adriamycin Resistance. To investigate the relationship between IncRNA FOXD2-AS1 and drug resistance in breast cancer and breast cancer cells, we examined the expression of IncRNA FOXD2-AS1 in breast cancer tissues and cells using qRT-PCR. The results showed that the expression of IncRNA FOXD2-AS1 was significantly higher in breast cancer tissues than in paracancerous tissues (Figure 1(a), P < 0.05). In addition, we found that compared with normal breast cells (MCF-10A), the expression of IncRNA FOXD2-AS1 was significantly upregulated in breast cancer cells (MCF-7). In breast cancer drug-resistant cells (MCF-7/ADR), the expression was even higher (Figure 1(b)). Meanwhile, compared with the MCF-7 group, the cell survival rate of MCF-7/ADR cells was significantly increased at different concentrations of ADR, with the IC50 also increased considerably (Figures 1(c)–1(d), P < 0.05). This shows that MCF-7/ADR cells were extremely more resistant to ADR than MCF-7 cells, which may be related to IncRNA FOXD2-AS1 expression.

3.2. Knockdown of IncRNA FOXD2-AS1 Can Inhibit the Invasion and Migration of MCF-7/ADR Cells and Promote Cell Apoptosis. Further studying the effect of IncRNA FOXD2-AS1 expression on the invasion, migration, and apoptosis of the drug-resistant cell line MCF-7/ADR. We first transfected IncRNA FOXD2-AS1 overexpression vector and siRNA in MCF-7/ADR cells. The qRT-PCR results showed that after interference or overexpression of IncRNA FOXD2-AS1, the expression of IncRNA FOXD2-AS1 in MCF-7/ADR cells was significantly reduced or increased (Figure 2(a), P < 0.05), confirming the successful transfection (Figure 2(a), P < 0.05). The results of Transwell and scratch testing showed that after overexpression of IncRNA FOXD2-AS1, MCF-7/ADR cell invasion and migration increased while interference with the IncRNA FOXD2-AS1 expression could significantly inhibit cell invasion and migration (Figures 2(b) and 2(c), P < 0.05). In addition, the flow cytometry results (Figure 2(d), P < 0.05) showed that compared with the vector group, the IncRNA FOXD2-AS1 group had significantly reduced cell apoptosis. Compared with the siNC group, cell apoptosis increased significantly after interfering with the expression of IncRNA FOXD2-AS1. These results suggest that interfering with the expression of IncRNA FOXD2-AS1 can inhibit the metastasis of MCF-7/ADR cells and promote their apoptosis.

3.3. Downregulation of IncRNA FOXD2-AS1 Can Improve the Chemosensitivity of MCF-7-ADR Cells. To further validate the effect of IncRNA FOXD2-AS1 on drug resistance in breast cancer cells, CCK-8 assay was used to detect the cell survival rate of each group of cells under the treatment of commonly used chemotherapeutic drugs ADR, cisplatin (DDP), and 5-fluorouracil (5-FU). The results showed that when IncRNA FOXD2-AS1 was overexpressed, cells’ survival rate and IC50 increased under ADR, DDP, and 5-FU treatments, indicating that their drug resistance was
enhanced. The cell survival rate and IC50 value decreased when knocked down (Figures 3(a)–3(f), \( P < 0.05 \)). This shows that downregulation of lncRNA FOXD2-AS1 could improve the sensitivity of drug-resistant cell lines.

3.4. Downregulation of lncRNA FOXD2-AS1 Can Inhibit PI3K/AKT Signaling Pathway in MCF-7/ADR Cells. Further investigation of the mechanism of lncRNA FOXD2-AS1 affecting breast cancer cells was done. The results showed that when IncRNA FOXD2-AS1 was overexpressed, the protein expression levels of p-PI3K and p-AKT increased significantly in cells. The p-PI3K/PI3K and p-AKT/AKT ratio also increased significantly, while the results were opposite after the knockdown of IncRNA FOXD2-AS1 (Figure 4, \( P < 0.05 \)). This indicates that the PI3K/AKT signaling pathway is involved in IncRNA FOXD2-AS1 regulating drug resistance of breast cancer cells.

4. Discussion

Breast cancer is the most common cancer among women. Its incidence ranks first among female malignant tumors [22]. The clinical treatment of breast cancer is mainly through chemotherapy [23, 24], but chemotherapeutic drugs are not only prone to multidrug resistance leading to poor therapeutic effects but also accompanied by severe nausea and vomiting, leukopenia, alopecia, phlebitis, and other adverse reactions. Therefore, finding new therapeutic targets for breast cancer is extremely urgent. IncRNA is considered to be an important regulator of cancer progression. It participates in multiple processes of gene expression regulation, plays a role in promoting or suppressing cancer in tumors, and is related to tumor cell proliferation, apoptosis, infiltration, metastasis, and other closely related malignant biological processes [25]. IncRNA FOXD2-AS1 is a newly discovered IncRNA that regulates the progression of cancer. A large number of studies have shown that IncRNA FOXD2-AS1 is upregulated in tumors and promotes the occurrence and development of tumors [26]. There are studies reporting IncRNA FOXD2-AS1 in papillary thyroid carcinoma, colorectal cancer, and bladder cancer are highly expressed and have a more significant correlation with poor prognosis, all of which can be used as molecular markers [17, 27, 28]. This indicates that IncRNA FOXD2-AS1 may play an essential role in cancer treatment. In this study, it was also found that the expression of IncRNA FOXD2-AS1 in breast cancer tissues, human breast cancer cells MCF-7, and multidrug-resistant strain MCF-7/ADR was significantly increased; the MCF-7/ADR expression levels were considerably higher than MCF-7 expression levels.
Figure 2: Continued.
Further research found that interference with lncRNA FOXD2-AS1 can inhibit the proliferation, invasion, and migration of MCF-7/ADR cells, promote cell apoptosis, and improve the chemical sensitivity of MCF-7/ADR cells. This is consistent with the results of Wang et al. [29]. Their experiments confirmed that overexpression of miR-134 in MCF-7/ADR cells could promote adriamycin-induced cell proliferation inhibition and proapoptosis, thereby increasing the sensitivity of breast cancer cells to adriamycin. These findings suggest that lncRNA FOXD2-AS1 can promote the proliferation and migration of breast cancer cells, inhibit apoptosis, affect the drug resistance of breast cancer cells, and promote the malignant biological behavior of breast cancer.

The PI3K/AKT signaling pathway is closely related to the life activities of the body and can regulate cell proliferation, protein synthesis, and its function and various life processes. PI3K, as a phosphatidylinositol kinase, can increase the phosphorylation level of the important downstream target gene AKT to promote AKT activation [30]. AKT is a protein kinase closely related to cell proliferation, apoptosis, and energy metabolism [31]. In addition, AKT is also associated with inflammation, immune regulation, and autophagy [32]. Studies have reported that AKR1B10 promotes breast cancer cell proliferation and migration through the PI3K/AKT/NF-κB signaling pathway [33]. At the same time, it was found that during the development of tamoxifen resistance, the changes of PI3K/AKT molecules before matrix...
Figure 3: The effect of lncRNA FOXD2-AS1 expression on the chemical sensitivity of MCF-7-ADR cells. CCK-8 assay was used to detect the cell survival rate of each group of MCF-7/ADR cells under ADR (a), DDP (b), and 5-FU (c) treatment; CCK-8 assay was used to detect the IC50 value of cells of each group of MCF-7/ADR cells under ADR (d), DDP (e), and 5-FU (f) treatment. *P < 0.05 vs. the MCF-7/ADR-vector group; ##P < 0.01 vs. the MCF-7/ADR-siNC group.
metallopeptidase overexpression are related to the poor prognosis of breast cancer patients [34]. This study found that interference with lncRNA FOXD2-AS1 can reduce p-PI3K and p-AKT protein expression levels, thereby inhibiting the PI3K/AKT signaling pathway, revealing that lncFOXD2-AS1 can increase protein expression levels of p-PI3K and p-AKT in breast cancer cells. This can further promote the PI3K/AKT signaling pathway and ultimately promote the occurrence and development of breast cancer, providing new clues for the research on the mechanism of breast cancer cell development. However, the specific mechanism in the animal models remains to be further elucidated.

In summary, the expression of lncRNA FOXD2-AS1 is upregulated in breast cancer and drug-resistant strains. Interfering with lncRNA FOXD2-AS1 can inhibit the proliferation, invasion, and migration of breast cancer cells, promote cell apoptosis, improve the chemical sensitivity of MCF-7/ADR cells, and inhibit the PI3K/AKT signaling pathway. Therefore, lncRNA FOXD2-AS1 can be used as a potential target for early diagnosis and targeted breast cancer therapy.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

This study was approved by the Medical Ethics Committee of the Peking University of Shenzhen Hospital (2020-023).

Conflicts of Interest

The authors claim that there is no conflict of interest between them.

References

[1] H. Kantarjian and P. P. Yu, “Artificial intelligence, big data, and cancer,” JAMA Oncology, vol. 1, no. 5, pp. 573-574, 2015.
[2] M. Jia, R. Zheng, S. Zhang, H. Zeng, X. Zou, and W. Chen, “Female breast cancer incidence and mortality in 2011, China,” Journal of Thoracic Disease, vol. 7, no. 7, pp. 1221–1226, 2015.
[3] L. Zhang, X. Zheng, A. Shen et al., “Long noncoding RNA RP11-70C1.3 confers chemoresistance of breast cancer cells through miR-6736-3p/NRP-1 axis,” Bosnian Journal of Basic Medical Sciences, 2021.
[4] H. Q. Ta, K. S. Thomas, R. S. Schrecengost, and A. H. Bouton, “A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells,” Cancer Research, vol. 68, no. 21, pp. 8796–8804, 2008.
[5] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.
[6] K. Kim, E. K. Chie, W. Han et al., “Prognostic factors affecting the outcome of salvage radiotherapy for isolated locoregional recurrence after mastectomy,” American Journal of Clinical Oncology, vol. 33, no. 1, pp. 23–27, 2010.
[7] R. A. Gupta, N. Shah, K. C. Wang et al., “Long non-coding RNA _HOTAIR_ reprograms chromatin state to promote cancer metastasis,” Nature, vol. 464, no. 7291, pp. 1071–1076, 2010.
[8] K. P. Sørensen, M. Thomassen, Q. Tan et al., “Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer,” Breast Cancer Research and Treatment, vol. 142, no. 3, pp. 529–536, 2013.
[9] P. Ji, S. Diederichs, W. Wang et al., “MALAT-1, a novel non-coding RNA, and thymosin _β_ 4 predict metastasis and survival in early-stage non-small cell lung cancer,” Oncogene, vol. 22, no. 39, pp. 8031–8041, 2003.
[10] G. X. Zheng, B. T. Do, D. E. Webster, P. A. Khavari, and H. Y. Chang, “Dicer-microRNA-Myc circuit promotes transcription of hundreds of long noncoding RNAs,” Nature Structural & Molecular Biology, vol. 21, no. 7, pp. 585–590, 2014.
[11] Q. Shi, Y. Li, S. Li et al., “LncRNA DILAL1 inhibits cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer,” *Nature Communications*, vol. 11, no. 1, 2020.

[12] Z. Chen, T. Pan, D. Jiang et al., “The lncRNA-GASS/miR-221-3p/DKK2 Axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the Wnt/β-catenin signaling pathway,” *Molecular Therapy - Nucleic Acids*, vol. 19, pp. 1434–1448, 2020.

[13] M. Zhang, F. Wang, Z. Xiang, T. Huang, and W. B. Zhou, “LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN,” *Clinical and Experimental Pharmacology & Physiology*, vol. 47, no. 8, pp. 1464–1472, 2020.

[14] J. Zhang, D. Fan, Z. Jian, G. G. Chen, and P. B. Lai, “Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma,” *PLoS One*, vol. 10, no. 10, article e0141042, 2015.

[15] J. Gao, F. Liu, X. Zhao, and P. Zhang, “Long non-coding RNA FOXD2-AS1 promotes proliferation, migration and invasion of ovarian cancer cells via regulation of miR-4492,” *Experimental and Therapeutic Medicine*, vol. 21, no. 4, p. 307, 2021.

[16] T. P. Xu, W. Y. Wang, P. Ma et al., “Upregulation of the long noncoding RNA _FOXD2-AS1_ promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1,” *Cell Death & Disease*, vol. 9, no. 2, p. 233, 2018.

[17] P. Ge, L. Cao, Y. J. Yao, R. J. Jing, W. Wang, and H. J. Li, “IncrRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p-SIX1 axis,” *Oncotargets and Therapy*, vol. 12, pp. 6105–6117, 2019.

[18] N. Gu, X. Wang, Z. di et al., “Silencing IncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis,” *Aging*, vol. 11, no. 22, pp. 10266–10283, 2019.

[19] M. Jiang, N. Qiu, H. Xia, H. Liang, H. Li, and X. Ao, “Long non-coding RNA FOXD2-AS1/miR-150-5p/PFN2 axis regulates breast cancer malignancy and tumorigenesis,” *International Journal of Oncology*, vol. 54, no. 3, pp. 1043–1052, 2019.

[20] J. Zhu, B. Liu, Z. Wang et al., “Exosomes from nicotine-stimulated macrophages accelerate atherosclerosis through miR-21-3p/PTEN-mediated VSMC migration and proliferation,” *Theranostics*, vol. 9, no. 23, pp. 6901–6919, 2019.

[21] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” *International Journal of Cancer*, vol. 136, no. 5, pp. E359–E386, 2015.

[22] N. F. Pondé, D. Zardavas, and M. Piccart, “Progress in adjuvant systemic therapy for breast cancer,” *Nature Reviews. Clinical Oncology*, vol. 16, no. 1, pp. 27–44, 2019.

[23] M. H. Redden and G. M. Fuhrman, “Neoadjuvant chemotherapy in the treatment of breast cancer,” *The Surgical Clinics of North America*, vol. 93, no. 2, pp. 493–499, 2013.